Nikolay Pimenov

Dr. Nikolay Pimenov

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
AKAnastasiya Kostyusheva
Anastasiya Kostyusheva
SBSergey Brezgin
Sergey Brezgin
NPNatalia Ponomareva
Natalia Ponomareva
VGVladimir Gegechkori
Vladimir Gegechkori
DKDmitry Kostyushev
Dmitry Kostyushev
CRISPR/Cas is a powerful tool for studying the role of genes in viral infections. The invention of CRISPR screening technologies has made it possible to untangle complex interactions between the host and viral agents. Moreover, whole-genome and pathway-specific CRISPR screens have facilitated identification of novel drug candidates for treating viral infections. In this review, we highlight recent developments in the fields of CRISPR/Cas with a focus on the use of CRISPR screens for studying viral infections and identifying new candidate genes to aid development of antivirals.

6 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
NPNikolay Pimenov
Nikolay Pimenov
DKDmitry Kostyushev
Dmitry Kostyushev
SKSvetlana Komarova
Svetlana Komarova
AFAnastasia Fomicheva
Anastasia Fomicheva
AUAleksandr Urtikov
Aleksandr Urtikov
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
The hepatitis C virus (HCV) causes both acute and chronic infection of the liver that can lead to liver cirrhosis, cancer, and liver failure. HCV is characterized by high genetic diversity and substantial variations in the prevalence of specific HCV genotypes throughout the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. Additionally, genotype-specific treatments for HCV are being actively employed in national plans for eliminating HCV infection around the world. The evaluation of HCV genotype prevalence in a given country is necessary for the successful implementation of the HCV elimination plans and for allocating financial resources to the DAAs which are the most effective against those specific HCV genotypes prevalent in a given country. Here, we analyzed HCV genotypes, subgenotypes, and recombinants in 10,107 serum samples collected in 2015–2017 from patients with chronic HCV infection living in all federal districts of Russia. This is the first and largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia from 2001 to 2021. We demonstrate that the incidence of acute HCV (AHC) infection in Russia decreased from 16.7 cases per 100,000 people in 2001 to 0.6/100,000 in 2021. The number of cases of chronic HCV (CHC) infection also decreased from 29.5 to 16.4 per 100,000 people during this period. The HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%), while genotypes 3 and 2 were detected in 35.4% and 7.8% of patients, respectively. These proportions are virtually identical in all regions of Russia except for the Far East, where HCV genotype 2 was detected in only 1% of the samples. HCV genotypes 1 and 2 are more widespread in women, and HCV genotype 3 in men. Genotype 3 was the most prevalent in 31–40-year-olds (44.9%), and genotype 1 was most prevalent in those over 70 years of age (72.2%). HCV genotype 2 was predominant among HCV-infected persons older than 40 years. Discriminating between HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment. For the first time, we demonstrate, here, countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b makes up 3.2% of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the North-West (60%), Southern (41.6%), and Central (31.6%) federal districts; its frequency in the Far Eastern and North Caucasus districts was ~14.3%. HCV RF1_2k/1b, and it was not detected in the Volga, Ural, or Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia.

15 June 2012 in Epidemiology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
NPNikolay Pimenov
Nikolay Pimenov
VCV. P. Chulanov
V. P. Chulanov
SKS. V Komarova
S. V Komarova
IKI. V. Karandashova
I. V. Karandashova
ANA. D. Neverov
A. D. Neverov
МВМихайловская Галина Валентиновна
Михайловская Галина Валентиновна
The article presents the results of analysis of reported incidence of acute and chronic hepatitis С in Russian Federation. Detailed description of current epidemiological characteristics of acute and chronic hepatitis С in various Federal regions and in different age groups is provided. The authors discuss the most probable transmission routs of HCV and its genotype distribution in Russia. Critical problems of laboratory diagnosis and hepatitis С surveillance are reviewed. There is an urgent need for introduction of HCV RNA as a routine confirmatory test for acute and chronic hepatitis С as well as introduction of Viral Hepatitis Registry for HCV patients throughout the entire territory of the Russian Federation.

2 November 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
NPNikolay Pimenov
Nikolay Pimenov
DKDmitry Kostyushev
Dmitry Kostyushev
SKSvetlana Komarova
Svetlana Komarova
AFAnastasia Fomicheva
Anastasia Fomicheva
AUAleksandr Urtikov
Aleksandr Urtikov
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
Hepatitis C virus (HCV) causes both acute and chronic disease of the liver that can lead to liver cirrhosis, cancer and liver failure. HCV is characterized by high genetic diversity and substantial variations in prevalence of specific HCV genotypes in different countries of the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. However, genotype-specific treatments for HCV are being actively employed in the national plans for elimination of HCV infection around the world. Evaluation of HCV genotype prevalence in a country is mandatory for successful implementation of the national plans for elimination of HCV infection and allocation of financial resources to DAAs most effecting for specific HCV genotypes prevalent in a country. Here, we analyzed HCV genotypes, subgenotypes and recombinants in 10,107 serum samples from patients with chronic HCV infection from all Federal districts of Russia collected in 2015-2017. This is the first, largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central Federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia in 2001-2021. We demonstrate that the incidence of acute HCV infection in Russia reduced from 16.7 cases per 100,000 population in 2001 to 0.6 cases per 100,000 population in 2021. The number of cases of chronic HCV infection decreased from 29.5 to 16.4 per 100,000 population during this period. HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%). Genotypes 3 and 2 were detected in 35.4% and 7.8% of patients respectively. These proportions are virtually identical in all regions of Russia except for Far East, where HCV genotype 2 amounts only to 1%. HCV genotypes 1 and 2 are more widespread in women, while HCV genotype 3 in men. The highest frequency of identification of genotype 3 was found in the age group of 31-40 years old (44.9%, respectively), and genotype 1 was more prevalent in a group of over 70 years old (72.2%). The proportion of HCV genotype 2 is predominant among HCV-infected persons older than 40 years. Discriminating HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment of such patients. For the first time, we demonstrate the countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b amounts to 3.2% in the structure of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the north-west (60%), southern (41.6%) and central (31.6%) federal district. Its frequency in Far Eastern and North Caucasus Districts was ~ 14.3%. HCV RF1_2k/1b was not detected in the Volga, Ural and Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia.

2 December 2022 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
LLLadnaia N.N. Ladnaia
Ladnaia N.N. Ladnaia
DDDementyeva L.A. Dementyeva
Dementyeva L.A. Dementyeva
KKKurganova O.P. Kurganova
Kurganova O.P. Kurganova
PAPloskireva A.A. Ploskireva A
Ploskireva A.A. Ploskireva A
NPNikolay Pimenov
Nikolay Pimenov
MWMoscow Russian Federal Service For Supervision Of Consumer Rights Protection And Human Well-Being
Moscow Russian Federal Service For Supervision Of Consumer Rights Protection And Human Well-Being

15 November 2020 in Epidemiology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAnastasia A. Fomicheva
Anastasia A. Fomicheva
NPNikolay Pimenov
Nikolay Pimenov
SKSvetlana V. Komarova
Svetlana V. Komarova
AUAleksandr Urtikov
Aleksandr Urtikov
OPOlga A. Paevskaya
Olga A. Paevskaya
ЦНЦапкова Наталья
Цапкова Наталья
BACKGROUND: Hepatitis B is an urgent medical and social problem in Russia. AIM: To determine the epidemiological features of the hepatitis B in the Russian Arctic. MATERIALS AND METHODS: We carried out a retrospective analysis of the incidence of hepatitis B (acute and chronic forms) in 9 Russian Arctic regions, 3 subarctic regions (Khanty-Mansiysk Autonomous Okrug, Magadan Region, Kamchatka Territory) and Russian Federation in 19992019. We also studied the prevalence of chronic hepatitis B and vaccination data against hepatitis B in these territories. RESULTS: From 1999 to 2019 the incidence of acute hepatitis B in three subarctic regions decreased 166 times (from 66.5 to 0.4 per 100 thousand population), in the Arctic zone of 74.5 times (from 29.8 to 0.4 per 100 thousand population) and 73 times in Russia (from 43.8 to 0.6). The incidence of chronic hepatitis forms in the same period in the Arctic zone decreased by 8.6 times (from 140.1 to 16.3), 5.8 times in the subarctic regions (from 116.6 to 20.0) and 5.7 times in Russia (from 96.3 to 16.8). In 2018, the results of the prevalence of chronic hepatitis B in the Arctic zone (697.3) was higher than in Russia by 98% (352.1) and higher in the subarctic regions by 67% (588.6). Timely coverage of hepatitis vaccination in children aged 12 months in the Russian Federation, the Arctic zone and the subarctic regions is maintained at a high level (more than 90%) from 2004 in 2019. Coverage of children by vaccination to 17 years inclusive and adults up to 35 years on these territories also exceeded 90%. CONCLUSIONS: Vaccination against hepatitis B in the Russian Federation led to a significant decrease in the incidence of this infection in the Russian Arctic. High prevalence of infection indicates the need to continue the program of mass vaccination and the timely introduction of the first dose of vaccine newborns. To reduce the risk of cirrhosis and liver cancer, it is necessary to increase the availability of diagnosis of the disease and its possible outcomes in the Arctic regions and timely provision of antiviral treatment of all patients.